2024
Estimating the lives that could be saved by expanded access to weight-loss drugs
Pandey A, Ye Y, Wells C, Singer B, Galvani A. Estimating the lives that could be saved by expanded access to weight-loss drugs. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2412872121. PMID: 39405358, PMCID: PMC11513960, DOI: 10.1073/pnas.2412872121.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Body mass index categoriesObesity prevalence dataGlucagon-like peptide-1 receptor agonistsHazard ratio of mortalityRatio of mortalityPublic health impactWeight loss drugsInsurance coverage issuesGastric inhibitory polypeptideHealthcare accessType 2 diabetesUnited StatesPublic health crisisObesity epidemicReceptor agonistsIndex categoriesHazard ratioPrevalence dataInhibitory polypeptidePeptide-1Health impactsNovel treatmentObesityHealth crisisMortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States
Pandey A, Fitzpatrick M, Singer B, Galvani A. Mortality and morbidity ramifications of proposed retractions in healthcare coverage for the United States. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321494121. PMID: 38648491, PMCID: PMC11066981, DOI: 10.1073/pnas.2321494121.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansInsurance CoverageInsurance, HealthMaleMedicaidMedicareMorbidityMortalityUnited States
2022
Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic
Galvani AP, Parpia AS, Pandey A, Sah P, Colón K, Friedman G, Campbell T, Kahn JG, Singer BH, Fitzpatrick MC. Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2200536119. PMID: 35696578, PMCID: PMC9231482, DOI: 10.1073/pnas.2200536119.Peer-Reviewed Original Research
2021
Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study
Du Z, Pandey A, Bai Y, Fitzpatrick MC, Chinazzi M, Pastore Y Piontti A, Lachmann M, Vespignani A, Cowling BJ, Galvani AP, Meyers LA. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. The Lancet Public Health 2021, 6: e184-e191. PMID: 33549196, PMCID: PMC7862022, DOI: 10.1016/s2468-2667(21)00002-5.Peer-Reviewed Original ResearchConceptsLow transmission scenarioSARS-CoV-2 testing programSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2SARS-CoV-2 transmissionSymptom-based testingSyndrome coronavirus 2Viral load dynamicsYLL avertedSARS-CoV-2 testing strategyTesting strategiesPositive test resultsCOVID-19 pandemicYears of lifeIsolation periodCoronavirus 2US National InstitutesViral testingPhysical distancing measuresEfficacious vaccineUS CentersAntiviral drugsIsolation durationEffective reproduction number